Related Experiment Video

Updated: May 26, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Adherence rate to beclomethasone dipropionate and the level of asthma control

Nulma S Jentzsch1, Paulo Camargos, Emanuel S C Sarinho

  • 1Department of Pediatrics and Postgraduate Institute, Medical Sciences School, Lucas Machado Foundation, Brazil.

Respiratory Medicine
|December 23, 2011
PubMed

Insights

High adherence to inhaled corticosteroids (ICS) improves asthma control in children. Even a 300 μg daily dose of beclomethasone dipropionate (BDP) can effectively manage persistent asthma.

Area of Science:

  • Pediatric Pulmonology
  • Allergy and Immunology
  • Pharmacotherapy Adherence

Background:

  • Limited research exists on the link between electronic monitoring of inhaled corticosteroid (ICS) adherence and childhood asthma control.
  • Persistent asthma in children requires effective management strategies, including optimal medication adherence.

Purpose of the Study:

  • To investigate the relationship between adherence to beclomethasone dipropionate (BDP) and asthma control levels in children.
  • To identify factors contributing to poor asthma control in pediatric patients.

Main Methods:

  • A prospective cohort study involving 102 steroid-naïve children (5-14 years) with persistent asthma.
  • Participants received 500-750 μg daily of BDP-CFC, with adherence electronically monitored at 4, 8, and 12 months.
  • Asthma control was categorized as 'controlled' or 'uncontrolled'.

Main Results:

  • Mean adherence rates were higher in children with controlled asthma, decreasing from 60.4% to 49.8% over 12 months (p=0.038).
  • In contrast, adherence decreased from 43.8% to 31.2% in children with uncontrolled asthma (p=0.001).
  • Multivariate analysis confirmed a significant independent association between asthma control and adherence rates (p≤0.005).

Conclusions:

  • Asthma control is directly proportional to adherence rates in pediatric patients.
  • A daily BDP dose of 300 μg may be sufficient for controlling mild to moderate persistent asthma, including exercise-induced asthma.

More Related Videos

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation09:42

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Published on: November 8, 2013

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...